
TG Therapeutics Inc. (NASDAQ:TGTX) shares advanced Wednesday after the biopharmaceutical company announced the completion of a $100 million share repurchase program and unveiled plans for an additional $100 million buyback authorization.
Trading volume reached 1.78 million shares, compared with an average of 2.06 million, according to Benzinga Pro.